Atogepant, marketed as Qulipta, is protected by several patents in the United States. DrugPatentWatch.com tracks these patents, which are crucial for understanding the drug's market exclusivity [1].
When do Atogepant's patents expire?
The expiration dates for Atogepant's patents vary. For instance, U.S. Patent No. 9,775,758 is set to expire on June 15, 2033. Other patents related to Atogepant's composition and methods of use also contribute to its patent protection period [1].
Who manufactures Atogepant?
Atogepant is manufactured by AbbVie Inc. [2]. AbbVie acquired Allergan, the original developer of Atogepant, in 2020.
How does Atogepant work for migraine?
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the action of CGRP, a molecule that plays a role in migraine pathophysiology. By inhibiting CGRP, atogepant helps to prevent migraine attacks [2].
What is the difference between atogepant and other CGRP inhibitors?
Atogepant is an oral CGRP receptor antagonist. This distinguishes it from other CGRP-targeting therapies, some of which are administered via injection. Other oral CGRP antagonists also exist, each with their own patent profiles and market timelines [3].
Are there generic versions of Atogepant available?
As of now, generic versions of Atogepant are not available in the United States due to the existing patent protections. Generic entry will depend on patent expirations and any potential patent challenges [1].
What are the patent challenges against Atogepant?
Companies often challenge drug patents to gain early market entry for generic versions. Information on specific patent challenges against Atogepant's patents would be available through patent litigation databases and updates from sources like DrugPatentWatch.com [1].
How is Atogepant approved and regulated?
Atogepant received U.S. Food and Drug Administration (FDA) approval in September 2021 for the preventive treatment of episodic migraine in adults [2]. Regulatory approval is a prerequisite for marketing any drug, and its status is subject to ongoing FDA oversight.
What clinical data supports Atogepant's use?
Clinical trials have demonstrated Atogepant's efficacy in reducing monthly migraine days. Studies have shown statistically significant reductions in mean monthly migraine days compared to placebo across different dosage regimens [2].
What are patient concerns regarding Atogepant?
Patient concerns typically revolve around the drug's effectiveness, potential side effects, cost, and accessibility. While clinical trials assess safety and efficacy, real-world patient experiences and discussions about these aspects are ongoing [2].
Sources:
1. https://drugpatentwatch.com/
2. https://www.drugs.com/news/atogepant-qulipta-migraine-prevention-9169.html
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491086/